Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. is a phase 2, randomised interventional study registered as NCT06911684 by Sun Yat-sen University, with a registry enrolment figure of 88 participants, started 2025-04-30 and due to reach its primary completion in 2026-04-30. Interventions recorded: lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy; lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy. Conditions listed: Rectal Cancer Patients. Primary outcome: Complete response (CR). Colorectal eligibility wording from the registry: "Pathology: Histologically confirmed rectal adenocarcinoma, with the lower tumor edge ≤12 cm from the anal verge". Sites: China. No results are recorded here; the registry entry is the source.